在ORATORIO试验中评估原发性进展型多发性硬化患者的无进展或无活动性疾病(NEPAD)
该事后分析基于安慰剂对照III期ORATORIO研究,评估奥瑞利珠单抗对原发性进展型多发性硬化患者NEPAD(无进展且无活动性疾病)及其组分的影响。从基线至第120周,奥瑞利珠单抗组维持NEPAD的比例为29.9%,安慰剂组为9.4%(相对风险3.15,95%CI 2.07-4.79,p<0.001);维持NEP的比例分别为42.7%和29.1%(相对风险1.47,95%CI 1.17-1.84,p<0.001)。与安慰剂相比,奥瑞利珠单抗使无进展或无炎症性疾病活动的PPMS患者比例增加3倍。
要点
- 从基线至第120周,奥瑞利珠单抗组29.9%维持NEPAD,安慰剂组为9.4%(相对风险3.15,p<0.001)。
- 奥瑞利珠单抗组42.7%维持NEP,安慰剂组为29.1%(相对风险1.47,p<0.001)。
- NEPAD可能代表PPMS患者疾病控制的敏感且有意义综合指标。
核心结论
- 与安慰剂相比,奥瑞利珠单抗使无进展或无炎症性疾病活动的PPMS患者比例增加3倍。
- NEPAD可能代表PPMS患者疾病控制的敏感且有意义综合指标。
研究设计与样本
- 安慰剂对照III期ORATORIO研究(NCT01194570)的事后分析。
- 奥瑞利珠单抗组600 mg,n=465;安慰剂组n=234。
- 评估从基线至第120周维持NEPAD及其组分的患者比例。
主要发现
- 从基线至第120周,奥瑞利珠单抗组29.9%维持NEPAD,安慰剂组为9.4%(相对风险3.15,95%CI 2.07-4.79,p<0.001)。
- 从基线至第120周,奥瑞利珠单抗组42.7%维持NEP,安慰剂组为29.1%(相对风险1.47,95%CI 1.17-1.84,p<0.001)。
- 对NEPAD和NEP各组分的影响与复合结局一致。
- 大多数ORATORIO研究的PPMS患者经历了临床进展或疾病活动证据。
关键数值与推荐
- NEPAD定义为无NEP、无脑MRI活动(无新发/扩大T2病灶且无T1钆增强病灶)且无方案定义的复发。
- NEP定义为无12周确认的EDSS进展(基线评分≤5.5分时进展≥1分,>5.5分时进展≥0.5分)。
- NEP还要求无12周确认的T25FW和9-HPT进展≥20%。
局限性
- 该研究为事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: No evidence of progression or active disease (NEPAD) is a novel combined endpoint defined by the absence of both progression and inflammatory disease activity in primary progressive multiple sclerosis (PPMS). In the placebo-controlled phase III ORATORIO study (NCT01194570), we investigated the effect of ocrelizumab on this comprehensive outcome and its components in a post-hoc analysis. METHODS: The proportion of patients with NEPAD (no evidence of progression [NEP; no 12-week confirmed progression of ≥1/≥0.5 points on the Expanded Disability Status Scale if the baseline score was ≤5.5/>5.5 points, respectively; no 12-week confirmed progression of ≥20% on the Timed 25-Foot Walk test and 9-Hole Peg Test], no brain magnetic resonance imaging activity [no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions], and no protocol-defined relapse) from baseline to week 120 was determined in ocrelizumab- (600 mg; n = 465) and placebo-treated (n = 234) patients. RESULTS: The majority of ORATORIO study patients with PPMS experienced clinical progression or evidence of disease activity. From baseline to week 120, 29.9% and 42.7% ocrelizumab-treated compared to 9.4% and 29.1% placebo-treated patients maintained NEPAD (relative risk [95% confidence interval {CI}], 3.15 [2.07-4.79]; p < 0.001) and NEP (relative risk [95% CI], 1.47 [1.17-1.84]; p < 0.001), respectively. Effects on the individual components of both measures were consistent with the compound outcomes. INTERPRETATION: Compared to placebo, ocrelizumab enhanced 3-fold the proportion of PPMS patients with no evidence of either progression or inflammatory disease activity. NEPAD may represent a sensitive and meaningful comprehensive measure of disease control in patients with PPMS. Ann Neurol 2018;84:527-536.
引用
- Wolinsky JS, Montalban X, Hauser SL, et al. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Ann Neurol. 2018. PMID: 30155979. doi:10.1002/ana.25313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。